TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04329494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given via PIPAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given via PIPAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraperitoneal Chemotherapy
Description: Undergo PIPAC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraperitoneal Chemotherapy
Description: Undergo PIPAC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraperitoneal Chemotherapy
Description: Undergo PIPAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Given via PIPAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given via PIPAC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02437084

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: Study subjects will receive atorvastatin 40 mg for 10 weeks.
Study: NCT03108508

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prod1
Description: 60 mL of product (water, silicic acid, Equisetum Arvense, Rosmarinus officinalis) (Silicic acid) equivalent to 21.6 mg of elemental silicon.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prod2
Description: 1.4 g of product (Orthosalicic acid) equivalent to 21.6 mg of elemental silicon

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prod3
Description: 120 mL of product (Aloe barbadensis Miller, organic silicon, potassium sorbate, cítric acid) (Organic silicon) equivalent to 21.6 mg of elemental silicon
Study: NCT03681613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEMEX program combined with a CNS-focused protocol
Description: The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.~The CNS-targeted treatment will consist of 12-week individualized and supervised sessions applied once weekly. Each training session will last approximately 30 minutes and include three parts, which are further explained below: 1) discussion of the participant's knee pain experience from a pain neuroscience perspective, 2) graded SDT and 3) GMI training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEMEX program
Description: The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.
Study: NCT02706379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local cerebral oxygen saturation
Description: take blood culture before antibiotic use;measure the blood lactate;liquid rescisutation as 20ml/kg
Study: NCT03693547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: utidelone injection
Description: utidelone monotherapy in patients with advanced NSCLC by utidelone
Study: NCT01888419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipotransplantation
Description: Lipotransplantation in general anaesthesia to the mastectomy site
Study: NCT02613169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: HIV-exposed uninfected infants will be randomized to receive either INH or no INH daily for 12 months for the prevention of Mycobacterium tuberculosis (MTB) infection.
Study: NCT03324919

Intervention type: BEHAVIORAL
Intervention: HRQL
Description: Intervention of patient centered care situation and health-related quality of life of patients with Psoriasis, Urticaria or Lupus erythematodes from non-urban practices vs urban practises. Identification of relevant health-related quality of life parameters of these patients.
Study: NCT04048226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine +Ketamine
Description: The patients in this group will be connected to the syringe pump that contain mixture of dexmedetomidine and ketamine with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery. The solution will contain 2 ug dexmedetomidine/ml and 1 mg ketamine/ml.
Study: NCT01634295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 2.5/40mg
Description: * Fixed dose combination of S-amlodipine 2.5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks.
Study: NCT03324919

Intervention type: BEHAVIORAL
Intervention: HRQL
Description: Intervention of patient centered care situation and health-related quality of life of patients with Psoriasis, Urticaria or Lupus erythematodes from non-urban practices vs urban practises. Identification of relevant health-related quality of life parameters of these patients.

Intervention type: BEHAVIORAL
Intervention: HRQL
Description: Intervention of patient centered care situation and health-related quality of life of patients with Psoriasis, Urticaria or Lupus erythematodes from non-urban practices vs urban practises. Identification of relevant health-related quality of life parameters of these patients.
Study: NCT00884832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
Study: NCT04370379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI302 (the first dose level)
Description: q4week (3 injections) followed by PRN dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI302 (the second dose level)
Description: q4week (3 injections) followed by PRN dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: 2mg, q4week (3 injections) followed by q8week
Study: NCT02337985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
Description: Given IV
Study: NCT01571453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: 10 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine extended release
Description: 150 mg/day
Study: NCT04971941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Vibe
Description: Use of Dental Vibe during dental anesthesia intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Vibe
Description: Use of Dental Vibe during dental anesthesia intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Vibe
Description: Use of Dental Vibe during dental anesthesia intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Vibe
Description: Use of Dental Vibe during dental anesthesia intervention
Study: NCT00129961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine or tacrolimus
Study: NCT03590249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: Osteopathic manipulation involves a number of different manual (hands-on) techniques. These include muscle inhibition (applying pressure to a muscle to induce relaxation); myofascial release (applying pressure to the fascia and moving it toward/away from a strain); muscle energy stretch (contraction of a stretching muscle); counterstrain (shortening a strained muscle); facilitated positional release (moving a vertebra into a restriction and applying a gentle compression); osteopathy in the cranial field (balancing the cranial tissue); balanced ligamentous tension/ligamentous articular strain (moving a joint into ease to release tension in the ligament); one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure. Treatment will last approximately 45 minutes.
Study: NCT00849862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: 750 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keppra®
Description: 750 mg Tablet
Study: NCT02373514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 1 gr paracetamol in 100 ml saline with rapid infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen
Description: 50 mg dexketoprofen in 100 ml saline with rapid infusion
Study: NCT00169221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iressa (Gefitinib)
Description: postoperative chemoradiotherapy with cisplatin + gefitinib

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: chemoradiotherapy with cisplatin
Description: postoperative chemoradiotherapy with cisplatin
Study: NCT03871660

Intervention type: DEVICE
Group type: OTHER
Intervention: FreeStyle Libre Pro
Description: Flash glucose monitoring device. Measures patients interstitial glucose levels continuously.

Intervention type: DEVICE
Group type: OTHER
Intervention: FreeStyle Libre Pro
Description: Flash glucose monitoring device. Measures patients interstitial glucose levels continuously.
Study: NCT00778895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' influenza vaccine GSK1557482A
Description: one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' influenza vaccine GSK1557482A
Description: one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip
Description: one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
Study: NCT02967601

Intervention type: BEHAVIORAL
Intervention: STAI (State Trait Anxiety Inventory) questionaire
Description: Each patient would fill the STAI questionaire before Cesarean Section (on the same day, in the morning)
Study: NCT00908726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Each subject received both propofol formulations in a crossover fashion separated by a 7-day washout period, and the order of the drug administration was randomized. Subjects received both propofol formulations (Lipid emulsion propofol: Diprivan® and Microemulsion propofol: AquafolTM) during 60 min. The infusion rate was assigned according to a nonblinded, randomized design to 1.5, 3, 6, or 12 mg/kg/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Each subject received both propofol formulations in a crossover fashion separated by a 7-day washout period, and the order of the drug administration was randomized. Subjects received both propofol formulations (Lipid emulsion propofol: Diprivan® and Microemulsion propofol: AquafolTM) during 60 min. The infusion rate was assigned according to a nonblinded, randomized design to 1.5, 3, 6, or 12 mg/kg/hr.
Study: NCT00949325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus plus liposomal doxorubicin
Description: Patients were treated with temsirolimus (Torisel) weekly by IV and with liposomal doxorubicin (Doxil) (standard dose) by IV once every 28 days. Cohorts of patients receive sequentially increasing dose of temsirolimus until dose limiting toxicity (DLT) occurred and the maximally tolerated dose (MTD) was identified. The MTD dose was the standard dose of temsirolimus used for the remainder of the study. Dose modifications were based on protocol parameters for toxicities.
Study: NCT03273881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glucose solution and Insulin
Description: Women in group 1, will receive intravenous saline solution boosted with 5% glucose combined with 8 units of insulin at a rate of 125mL/h. The desirable intrapartum glucose level will be 70 to 100 mg/dL. Glucose levels will be checked hourly.~Glucose level between 100-140 mg/dL will be treated with additional intravenous insulin, 1 units/hour.~Glucose level between 141-160 mg/dL will be treated with intravenous insulin, 2 units/hour. Additionally, the 5% glucose solution will be substitute with lactated Ringer's solution.~Glucose level between 161-200 mg/dL will be treated with intravenous insulin, 4 units/hour.~Glucose level above 200 mg/dL will be treated with intravenous insulin, 6 units/hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glucose solution and Insulin
Description: Women in group 1, will receive intravenous saline solution boosted with 5% glucose combined with 8 units of insulin at a rate of 125mL/h. The desirable intrapartum glucose level will be 70 to 100 mg/dL. Glucose levels will be checked hourly.~Glucose level between 100-140 mg/dL will be treated with additional intravenous insulin, 1 units/hour.~Glucose level between 141-160 mg/dL will be treated with intravenous insulin, 2 units/hour. Additionally, the 5% glucose solution will be substitute with lactated Ringer's solution.~Glucose level between 161-200 mg/dL will be treated with intravenous insulin, 4 units/hour.~Glucose level above 200 mg/dL will be treated with intravenous insulin, 6 units/hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glucose solution only
Description: Women in group 2, will receive intravenous saline solution boosted with 5% glucose only, at a rate of 125mL/h. Women in this group will be treated similar to group 1 if glucose levels crossed over 100 mg/dL.
Study: NCT00574054

Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared
Description: Far infrared radiation (5 μm to 20 μm wavelength) for 30 to 40 minutes per treatment session.
Study: NCT01271920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study: NCT01510379

Intervention type: DEVICE
Group type: OTHER
Intervention: Reletex
Description: Neurostimulation device for prevention/treatment of post-operative nausea and vomiting, Reletex arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reletex
Description: Neurostimulation device for prevention/treatment of post-operative nausea and vomiting, Reletex arm.

Intervention type: DRUG
Group type: OTHER
Intervention: IV ondansetron 4 mg q 6 hours for a total of 4 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV ondansetron 4 mg q 6 hours for a total of 4 doses
Study: NCT00710242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF01
Description: Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
Study: NCT01634295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 5/40mg
Description: * Fixed dose combination of S-amlodipine 5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 5/80mg
Description: * Fixed dose combination of S-amlodipine 5mg and Telmisartan 80mg QD 6 weeks.~* With the others investigation product placebo 4 tabs QD 6 weeks.
Study: NCT04627233

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo group received normal saline in a same volume to match corresponding HEP-1 doses. Study drug was administered by qualified staff in research clinic settings; injections were given to abdominal sites on rotating basis, by anatomic quadrant.
Study: NCT03349840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec U100
Description: Patients on any basal insulin including insulin glargine will be randomised and converted to basal degludec insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Patients on any basal insulin including insulin glargine will be randomised and either glargine will be continued or will beconverted to basal glargine insulin
Study: NCT03699501

Intervention type: OTHER
Intervention: Questionnaires
Description: * A validated oral health-related quality of life self-assessment questionnaire: the GOHAI~* A validated oral health-related quality of life self-assessment questionnaire to be validated: SOHP~* A validated depression scale: the Beck scale~* A self-assessment questionnaire for oral health coping to be validated: the SCOOHP~* A validated self-assessment questionnaire for coping: The Brief cope)

Intervention type: OTHER
Intervention: Questionnaires
Description: * A validated oral health-related quality of life self-assessment questionnaire: the GOHAI~* A validated oral health-related quality of life self-assessment questionnaire to be validated: SOHP~* A validated depression scale: the Beck scale~* A self-assessment questionnaire for oral health coping to be validated: the SCOOHP~* A validated self-assessment questionnaire for coping: The Brief cope)

Intervention type: PROCEDURE
Intervention: Oral examination
Description: * An evaluation of dental health using the CAO index~* An evaluation of oral hygiene with the IHO-S index

Intervention type: PROCEDURE
Intervention: Oral examination
Description: * An evaluation of dental health using the CAO index~* An evaluation of oral hygiene with the IHO-S index
Study: NCT04232436

Intervention type: OTHER
Intervention: Survival at discharge
Description: Survival at discharge

Intervention type: OTHER
Intervention: Survival at discharge
Description: Survival at discharge

Intervention type: OTHER
Intervention: Survival without severe morbidity
Description: Survival without severe morbidity (IVH, severe BPD, NEC, ROP)

Intervention type: OTHER
Intervention: Survival without severe morbidity
Description: Survival without severe morbidity (IVH, severe BPD, NEC, ROP)
Study: NCT04365933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Oral tablets
Study: NCT01723475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAY2010112
Description: Subcutaneous (s.c.) administration once daily. Starting dose will be 0.5 µg ; dose will be escalated dependent on any dose limiting toxicities
Study: NCT03699501

Intervention type: OTHER
Intervention: questionnaires (test-retest)
Description: SCOOHP and SOHP questionnaires
Study: NCT00735163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced model predictive control algorithm (eMPC)
Description: eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
Study: NCT01723475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAY2010112
Description: Continuous intravenous infusion (c.i.v.) administration. Starting dose will be 5 µg ; dose will be escalated dependent on any dose limiting toxicities.
Study: NCT01942421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cultivated mucosal epithelial transplantation
Description: cultivated autologous mucosal epithelium, then transplant to limbal stem cell deficiency patients.
Study: NCT01634295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-amlodipine 2.5mg
Description: * S-amlodipine 2.5mg QD 4 weeks~* With the others investigation product placebo 4 tabs QD 4 weeks.
Study: NCT02322905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Therapy
Description: 8 sessions of ERT
Study: NCT02918812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracervical lidocaine
Description: Intracervical lidocaine injected at four different points

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Diclofenac
Description: Intramuscular Diclofenac 30 mins before HSG
Study: NCT03366207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Ciprofloxacin 250 mg PO twice daily (BID) x 3 days for women with uUTI.
Study: NCT01634295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-amlodipine 5mg
Description: * S-amlodipine 2.5mg QD 6weeks~* With the others investigation product placebo 4 tabs QD 6 weeks.